BiBB receives first European order from Palex Medical Spain
BiBBInstruments AB ("BiBB" or the "Company"), developer of EndoDrill® – the world's first market-cleared powered biopsy instrument for endoscopy – today announced that the Company has received its first order in Europe from its new partner, Palex Medical Spain ("Palex Spain"). Two weeks ago, BiBB signed an exclusive distribution agreement with Palex Spain, and the Company has now received its first order for EndoDrill® GI worth EUR 15,600 (corresponding to approximately KSEK 173). During the autumn, Palex Spain will initiate the commercial launch of EndoDrill® GI at selected key opinion leader (KOL) centres with significant EUS activity. The system will be showcased at national congresses in Spain. In parallel, BiBB is engaged in discussions regarding distribution agreements with additional companies within the Palex Group network.
Comment from Fredrik Lindblad, CEO of BiBB:
"The first order for EndoDrill® GI in Europe marks the beginning of an exciting market introduction in Spain, followed by the rest of Europe. Spain is a major market for endoscopic ultrasound, with approximately 100 hospitals performing EUS procedures. Palex Spain has a clear objective in its business plan: to establish EndoDrill® as the preferred solution for EUS tissue acquisition in Spain."
About Palex Group and Palex Medical Spain
Palex Group is a leading European distributor in healthcare and medical technology, providing advanced solutions and services to hospitals, healthcare professionals and research institutions. The Group operates through a network of specialised companies with expertise in endoscopy, surgery, interventional medicine and hospital solutions.
Palex Spain is the largest operating company within Palex Group, one of Europe's leading healthcare and medical technology distribution groups. The company has close to 1,000 employees and a dedicated endoscopy organisation serving leading hospitals throughout Spain.
About EndoDrill® GI
EndoDrill® GI is the world's first market-cleared powered biopsy instrument for endoscopic ultrasound (EUS), with both FDA 510(k) clearance and CE marking. Unlike conventional manual biopsy needles, EndoDrill® uses a powered rotating needle tip designed to obtain intact core tissue samples for histopathology and molecular analysis. The system is currently being commercialised in the United States through the Company's distribution partner, TaeWoong Medical USA. The European commercial launch is planned to begin in Spain during 2026 through the Company's distribution partner, Palex Medical Spain, representing the first step in BiBB's European expansion.
For more information, please contact:
Fredrik Lindblad, CEO
Email: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com
This is a translation of the Swedish press release. In the event of any discrepancy, the Swedish language version shall prevail.
The information was submitted for publication, through the agency of the contact person set out above, at the time stated by the Company's news distributor upon publication of this press release.
About BiBBInstruments AB
BiBBInstruments AB is a medical technology company focused on cancer diagnostics. The Company develops and manufactures EndoDrill®, the world's first family of market-cleared powered biopsy instruments for endoscopy. EndoDrill® is designed to obtain core needle biopsy (CNB) samples with high diagnostic accuracy and aims to improve the diagnosis of cancer in, among other organs, the stomach, pancreas, liver, lungs and urinary bladder. The product portfolio addresses the global market for ultrasound-guided endoscopic biopsy instruments (EUS/EBUS), one of the most advanced and fastest-growing segments within modern endoscopy. BiBB received FDA 510(k) clearance for EndoDrill® GI in 2023 and CE marking under the MDR for EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO in 2024. EndoDrill® is therefore the first powered biopsy system to be market-cleared in the United States and CE-marked in Europe. The U.S. launch of EndoDrill® GI commenced during the second half of 2025 together with TaeWoong Medical USA. The European launch begins in 2026 with the Company's partner, Palex Medical Spain. The EndoDrill® system consists of sterile single-use instruments and a proprietary drive system. BiBB was founded in 2013 by Dr Charles Walther, cancer researcher at Lund University and Senior Consultant Pathologist at Skåne University Hospital. The Company is headquartered at Medicon Village in Lund, Sweden, and its shares are listed on Spotlight Stock Market (ticker: BIBB).